Document Type


Subject Area(s)

Amikacin (pharmacokinetics, therapeutic use); Animals; Animals, Newborn; Anti-Bacterial Agents (pharmacokinetics, therapeutic use); Bacteremia (drug therapy, metabolism, veterinary); Female; Fluorescence Polarization Immunoassay (veterinary); Gram-Negative Bacterial Infections (drug therapy, metabolism, veterinary); Half-Life; Horse Diseases (drug therapy, metabolism); Horses (metabolism); Hypoxia (metabolism, veterinary); Male; Metabolic Clearance Rate (physiology); Microbial Sensitivity Tests (veterinary)


The objectives of this study were to investigate the pharmacokinetics of once-daily amikacin in healthy neonates, to determine amikacin concentrations in hospitalized foals, and to determine the minimum inhibitory concentrations (MICs) of amikacin against gram-negative isolates from blood cultures in septic foals. Median half-life, clearance, and volume of distribution of amikacin in healthy 2- to 3-day-old foals after administration of an intravenous bolus of amikacin (25 mg/kg) were 5.07 hours (4.86-5.45 hours), 1.82 mL/min/kg (1.35-1.97 mL/min/kg), and 0.785 L/kg (0.638-0.862 L/kg), respectively. Statistically significant (P or = 3 microg/mL between the 2 groups. An initial dose at 25 mg/kg is recommended for once-daily amikacin in equine neonates.

Digital Object Identifier (DOI)


©2004 by the American College of Veterinary InternalMedicine

APA Citation

Bucki, E., Giguere, S., Macpherson, M., & Davis, R. (2004). Pharmacokinetics of Once-Daily Amikacin in Healthy Foals and Therapeutic Drug Monitoring in Hospitalized Equine Neonates. Journal Of Veterinary Internal Medicine, 18(5), 728-733.